CN114072381A - 氨基硫醇类化合物作为脑神经或心脏保护剂的用途 - Google Patents

氨基硫醇类化合物作为脑神经或心脏保护剂的用途 Download PDF

Info

Publication number
CN114072381A
CN114072381A CN202080043052.0A CN202080043052A CN114072381A CN 114072381 A CN114072381 A CN 114072381A CN 202080043052 A CN202080043052 A CN 202080043052A CN 114072381 A CN114072381 A CN 114072381A
Authority
CN
China
Prior art keywords
compound
methylamino
mercapto
oxopropan
cerebral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080043052.0A
Other languages
English (en)
Other versions
CN114072381B (zh
Inventor
田红旗
刘雅红
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KECHOW PHARMA Inc
Original Assignee
KECHOW PHARMA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KECHOW PHARMA Inc filed Critical KECHOW PHARMA Inc
Publication of CN114072381A publication Critical patent/CN114072381A/zh
Application granted granted Critical
Publication of CN114072381B publication Critical patent/CN114072381B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D277/06—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/25—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C07C323/40—Y being a hydrogen or a carbon atom
    • C07C323/41—Y being a hydrogen or an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members

Abstract

本发明涉及氨基硫醇类化合物作为脑神经保护剂或心脏保护剂的用途，特别是在预防或治疗心脑血管疾病，例如心脑缺血再灌注损伤、脑卒中等疾病中的用途。

Description

PCT国内申请，说明书已公开。

Claims (13)

  1. PCT国内申请，权利要求书已公开。
CN202080043052.0A 2019-06-13 2020-06-13 氨基硫醇类化合物作为脑神经或心脏保护剂的用途 Active CN114072381B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2019/091065 2019-06-13
CN2019091065 2019-06-13
PCT/CN2020/095998 WO2020249120A1 (zh) 2019-06-13 2020-06-13 氨基硫醇类化合物作为脑神经或心脏保护剂的用途

Publications (2)

Publication Number Publication Date
CN114072381A true CN114072381A (zh) 2022-02-18
CN114072381B CN114072381B (zh) 2024-02-27

Family

ID=73781951

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080043052.0A Active CN114072381B (zh) 2019-06-13 2020-06-13 氨基硫醇类化合物作为脑神经或心脏保护剂的用途

Country Status (7)

Country Link
US (1) US20220259164A1 (zh)
EP (1) EP3984993A4 (zh)
JP (1) JP2022537518A (zh)
CN (1) CN114072381B (zh)
AU (1) AU2020293522B2 (zh)
CA (1) CA3142963A1 (zh)
WO (1) WO2020249120A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113768940A (zh) * 2021-08-25 2021-12-10 中国辐射防护研究院 一种放射性肺损伤的防护方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1283994A (zh) * 1997-12-09 2001-02-14 美国生物科学有限公司 使用氨基硫醇化合物治疗神经和肾疾病和治疗毒性的方法
CN1679488A (zh) * 2004-04-06 2005-10-12 欧莱雅 二巯基酰胺在永久性再成型角蛋白纤维中的应用
WO2010014953A1 (en) * 2008-08-01 2010-02-04 The Regents Of The University Of Colorado, A Body Corporate Prolonged administration of a dithiol anti-oxidant protects against ventricular remodeling
CN103772245A (zh) * 2012-10-26 2014-05-07 中国医学科学院放射医学研究所 取代的l-半胱氨酸类化合物及其制法和用途
CN106432014A (zh) * 2016-09-05 2017-02-22 中国医学科学院放射医学研究所 胺基硫醇类化合物及其制备方法和其在辐射防护中的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3047734B1 (fr) * 2016-02-17 2019-09-06 Advanced Biodesign Procede de preparation de composes aminothiolester et leurs sels

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1283994A (zh) * 1997-12-09 2001-02-14 美国生物科学有限公司 使用氨基硫醇化合物治疗神经和肾疾病和治疗毒性的方法
CN1679488A (zh) * 2004-04-06 2005-10-12 欧莱雅 二巯基酰胺在永久性再成型角蛋白纤维中的应用
WO2010014953A1 (en) * 2008-08-01 2010-02-04 The Regents Of The University Of Colorado, A Body Corporate Prolonged administration of a dithiol anti-oxidant protects against ventricular remodeling
CN103772245A (zh) * 2012-10-26 2014-05-07 中国医学科学院放射医学研究所 取代的l-半胱氨酸类化合物及其制法和用途
CN106432014A (zh) * 2016-09-05 2017-02-22 中国医学科学院放射医学研究所 胺基硫醇类化合物及其制备方法和其在辐射防护中的应用

Also Published As

Publication number Publication date
JP2022537518A (ja) 2022-08-26
EP3984993A4 (en) 2023-07-19
CA3142963A1 (en) 2020-12-17
AU2020293522B2 (en) 2024-01-25
AU2020293522A1 (en) 2022-01-20
US20220259164A1 (en) 2022-08-18
WO2020249120A9 (zh) 2021-12-16
CN114072381B (zh) 2024-02-27
WO2020249120A1 (zh) 2020-12-17
EP3984993A1 (en) 2022-04-20

Similar Documents

Publication Publication Date Title
US9382240B2 (en) Crystalline salts of a potent HCV inhibitor
KR101539588B1 (ko) (6，7-디히드로-2-니트로-5ｈ-이미다졸[2,1-ｂ][1,3]옥사진-6-일)아미드 화합물, 그의 제조방법 및 용도
DK2151439T3 (en) Nitrogenated AROMATIC 6-membered RINGDERIVAT, AND THIS pharmaceutical composition comprising
FI90545C (fi) Menetelmä terapeuttisesti aktiivisten 2,2-dimetyylikromeenijohdannaisten valmistamiseksi
EA022909B1 (ru) Соединение бензотиазолона
CN114072381A (zh) 氨基硫醇类化合物作为脑神经或心脏保护剂的用途
CN110964078A (zh) 具有抗肺癌作用的常春藤皂苷元类化合物h-x及其制备方法和应用
KR20190032418A (ko) 보티옥세틴 유사체와 용도 및 이의 제조
WO2020177291A1 (zh) 法舒地尔复合盐及其制备方法和用途
WO2023216533A1 (zh) 一种吲哚生物碱及其制备方法与应用
ES2691530T3 (es) 2,3,5-trihidroxi-androst-6-ona y métodos de preparación y uso de la misma
CN110857285B (zh) 取代吡唑类化合物、其制备方法、药物组合物及用途
CN106146612B (zh) 一类乙二醛酶i不可逆抑制剂及其制备方法和用途
CN112218878A (zh) Ntcp抑制剂
JP6078153B2 (ja) チアンジンアミド誘導体、並びにその医薬組成物及び使用
CN116003469B (zh) 嘧啶基抗病毒化合物的制备与使用方法
CN113166064B (zh) 胆碱酯酶抑制剂多晶型及其应用
KR101172472B1 (ko) 4급 암모늄 화합물, 그 제조 방법, 뇌혈관 장애 치료제 및 심장 질환 치료제
JP2023549962A (ja) Ｐｕ．１阻害剤としての化合物
CN113024507A (zh) 一种用于治疗脑损伤的含硫杂环化合物及其应用
CN115974719A (zh) 化合物、包括所述化合物的药物组合物及其用途
CN105037490B (zh) 一类乙二醛酶i不可逆抑制剂及其制备方法和用途
WO2023141207A1 (en) Esters of 8-methyl-8-azabicyclo[3.2.1] octan-3-yl 3-hydroxy-2-phenylpropanoate
KR20240046539A (ko) 12/15-리폭시게나제의 억제제
CN114249721A (zh) 长春胺peg衍生物与在制备治疗糖尿病周围神经病变、糖尿病足及肺纤维化药物中的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40060534

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant